CN101934071B - α-1-抗胰蛋白酶在制备用于治疗慢性疲劳综合症的药物中的用途 - Google Patents

α-1-抗胰蛋白酶在制备用于治疗慢性疲劳综合症的药物中的用途 Download PDF

Info

Publication number
CN101934071B
CN101934071B CN2010102168418A CN201010216841A CN101934071B CN 101934071 B CN101934071 B CN 101934071B CN 2010102168418 A CN2010102168418 A CN 2010102168418A CN 201010216841 A CN201010216841 A CN 201010216841A CN 101934071 B CN101934071 B CN 101934071B
Authority
CN
China
Prior art keywords
aat
cfs
antitrypsin
patient
chronic fatigue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2010102168418A
Other languages
English (en)
Chinese (zh)
Other versions
CN101934071A (zh
Inventor
安娜·加西亚·昆塔纳
乔斯·阿莱格里马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Probitas Pharma SA
Original Assignee
Probitas Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probitas Pharma SA filed Critical Probitas Pharma SA
Publication of CN101934071A publication Critical patent/CN101934071A/zh
Application granted granted Critical
Publication of CN101934071B publication Critical patent/CN101934071B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN2010102168418A 2009-06-30 2010-06-30 α-1-抗胰蛋白酶在制备用于治疗慢性疲劳综合症的药物中的用途 Active CN101934071B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200930387 2009-06-30
ES200930387A ES2332645B1 (es) 2009-06-30 2009-06-30 Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.

Publications (2)

Publication Number Publication Date
CN101934071A CN101934071A (zh) 2011-01-05
CN101934071B true CN101934071B (zh) 2012-11-28

Family

ID=41571181

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010102168418A Active CN101934071B (zh) 2009-06-30 2010-06-30 α-1-抗胰蛋白酶在制备用于治疗慢性疲劳综合症的药物中的用途

Country Status (16)

Country Link
US (1) US9205134B2 (https=)
EP (1) EP2289540B1 (https=)
JP (1) JP5231490B2 (https=)
CN (1) CN101934071B (https=)
AR (1) AR077123A1 (https=)
AU (1) AU2010202203B2 (https=)
BR (1) BRPI1002087B1 (https=)
CA (1) CA2706212C (https=)
CL (1) CL2010000575A1 (https=)
ES (2) ES2332645B1 (https=)
MX (1) MX2010006125A (https=)
NZ (1) NZ585890A (https=)
PL (1) PL2289540T3 (https=)
PT (1) PT2289540E (https=)
RU (1) RU2436590C1 (https=)
UY (1) UY32670A (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014014751A8 (pt) * 2011-12-19 2017-07-04 Lfb Usa Inc composição compreendendo alfa-1-antitripsina, células epiteliais de glândula mamária, mamífero não humano transgênico, e, método para reduzir a atividade de elastase no pulmão
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
US20220160847A1 (en) * 2020-11-20 2022-05-26 Mark Egly Method of preventing and/or treating a plurality of diseases
WO2023184473A1 (zh) * 2022-04-01 2023-10-05 首创生物技术有限公司 肽用于治疗神经退行性疾病或改善认知功能的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1554343A (zh) * 2000-04-21 2004-12-15 �������Ŷ���Լ��������˾ 用于治疗纤维肌痛和慢性疲劳综合症的化合物
CN1751739A (zh) * 2004-09-24 2006-03-29 基立福有限公司 α－1抗胰蛋白酶在制备用于治疗纤维肌痛的药物中的应用
WO2009042193A1 (en) * 2007-09-25 2009-04-02 Abbott Laboratories Octahydropentalene compounds as chemokine receptor antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2281222A (en) * 1941-09-27 1942-04-28 American Bosch Corp Speed regulator for internal combustion engines
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
EP0584185B1 (en) * 1991-05-14 1999-08-11 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2002006837A1 (en) * 2000-07-14 2002-01-24 Matsushita Electric Industrial Co., Ltd. Particle-labeled protein and immuno-chromatograph using the same
AU2003286258B2 (en) 2002-11-20 2006-12-21 Arriva-Prometic Inc. Composition and method for treating inflammatory diseases using protease inhibitors
US7344882B2 (en) * 2003-05-12 2008-03-18 Bristol-Myers Squibb Company Polynucleotides encoding variants of the TRP channel family member, LTRPC3
US7850970B2 (en) * 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
WO2006026837A1 (en) * 2004-09-07 2006-03-16 Patrick Englebienne Diagnostic methods for measuring elastase activity levels
EP2114141A2 (en) * 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
HUE030205T2 (en) 2007-11-02 2017-05-29 Grifols Therapeutics Inc A method, composition, and product for providing alpha-1-antitrypsin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1554343A (zh) * 2000-04-21 2004-12-15 �������Ŷ���Լ��������˾ 用于治疗纤维肌痛和慢性疲劳综合症的化合物
CN1751739A (zh) * 2004-09-24 2006-03-29 基立福有限公司 α－1抗胰蛋白酶在制备用于治疗纤维肌痛的药物中的应用
WO2009042193A1 (en) * 2007-09-25 2009-04-02 Abbott Laboratories Octahydropentalene compounds as chemokine receptor antagonists

Also Published As

Publication number Publication date
NZ585890A (en) 2011-11-25
AR077123A1 (es) 2011-08-03
AU2010202203A1 (en) 2011-01-20
CL2010000575A1 (es) 2011-10-28
US9205134B2 (en) 2015-12-08
US20100331261A1 (en) 2010-12-30
CA2706212C (en) 2014-02-04
BRPI1002087A2 (pt) 2012-03-13
EP2289540B1 (en) 2012-08-22
AU2010202203B2 (en) 2012-08-23
EP2289540A1 (en) 2011-03-02
MX2010006125A (es) 2011-01-05
ES2332645B1 (es) 2010-10-18
PL2289540T3 (pl) 2013-03-29
ES2392691T3 (es) 2012-12-12
CN101934071A (zh) 2011-01-05
JP2011012060A (ja) 2011-01-20
UY32670A (es) 2011-01-31
BRPI1002087B1 (pt) 2019-07-02
CA2706212A1 (en) 2010-12-30
RU2436590C1 (ru) 2011-12-20
HK1148198A1 (en) 2011-09-02
PT2289540E (pt) 2012-12-04
JP5231490B2 (ja) 2013-07-10
ES2332645A1 (es) 2010-02-09

Similar Documents

Publication Publication Date Title
TWI752907B (zh) 用於治療cln2疾病之tpp1調配物及方法
ES2371785T3 (es) Utilización de al menos una neurotoxina botulínica para tratar el dolor causado por los tratamientos terapéuticos del virus del sida.
CN101934071B (zh) α-1-抗胰蛋白酶在制备用于治疗慢性疲劳综合症的药物中的用途
Kubota et al. Cryopyrin-associated periodic syndromes: background and therapeutics
Riedl et al. Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement
Genovese et al. SAT0117 sarilumab, a subcutaneously-administered, fully-human monoclonal antibody inhibitor of the IL-6 receptor: Relationship between eular responses and change from baseline of selected clinical parameters
CN103649106A (zh) 用于治疗神经退行性和缺血性脑疾病的化合物和药学组合
Babaei et al. A Review of Phase III and Long‐Term Data for Deucravacitinib for Plaque Psoriasis
Li et al. Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks
Toussirot New onset of psoriasis in a patient with rheumatoid arthritis treated with rituximab
Koshy et al. When venom meets the heart: a rare case of scorpion sting-induced acute myocardial infarction
CN100388950C (zh) 人尿激肽原酶在制备治疗糖尿病合并脑梗死药物中的应用
HK1148198B (en) Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome
Wang et al. Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6‐month improvement.
RU2391100C1 (ru) Способ лечения больных грибковыми заболеваниями ногтей
Embry et al. Clinical Manifestations and Characterization of COVID-19
Dashtipour et al. AbobotulinumtoxinA using 2 mL dilution maintains durable functional improvements across multiple treatment cycles
WO2023280981A1 (en) Using c1 esterase inhibitor to treat viral infection-related symptoms
Kunz et al. The First Real-World Experience with Betibeglogene Autotemcel (beti-cel) Gene Therapy Treatment for Transfusion-Dependent β-Thalassemia (TDT)
Azuma et al. Improved response to infliximab after leukocytapheresis in a patent with rheumatoid arthritis
Van Den Broek et al. SAT0116 Safety and Efficacy of Ara290, a Non-Hematopoietic Erythropoietin Derived Peptide, in a 4 Weeks Phase II Open Label Trial in Patients with Active Rheumatoid Arthritis.
Pai et al. Antiretroviral agent entecavir exacerbates major depression.
CN111568899A (zh) 一种药物组合物及其在治疗鼻炎中的应用
Koepke et al. Short term effects of alpha1-antitrypsin substitution therapy on the degranulation of neutrophil granulocytes
Sakai et al. AB0530 Efficacy and Safety of Multi-Target Therapy Using a Combination of Cyclophosphamide and Tacrolimus in Patients with Refractory Lupus Nephritis: A Prospective, Single-Arm, Open-Label Study of 13 Patients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1148198

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1148198

Country of ref document: HK